EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will host an R&D Day in New York on September 24, 2014. Presentations by key opinion leaders will include the Company’s lead orphan disease program that uses genetically-modified autologous fibroblasts—developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology—to treat recessive dystrophic epidermolysis bullosa (RDEB), a debilitating, genetic skin disease. In addition, updates will be presented on two Phase II clinical trials for azficel-T, Fibrocell’s proprietary autologous fibroblast technology, for vocal cord scarring and restrictive burn scarring. Both studies leverage the Company’s existing BLA for azficel-T through supplemental drug applications to develop treatments for serious scarring conditions.
Attendance at R&D Day is by invitation only for institutional investors and equity analysts. If you are interested in attending, please contact Susan Noonan at firstname.lastname@example.org.
Presentations at R&D Day will be webcast live on the Fibrocell Science website: http://www.fibrocellscience.com/investors/events-and-presentations/. A replay of the event will be archived on the Fibrocell Science website for 30 days.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NASDAQ:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. Fibrocell is also pursuing medical applications for azficel-T—the Company’s proprietary autologous fibroblast technology—for restrictive burn scarring and vocal cord scarring. Both indications are currently in Phase II clinical trials. For additional information, visit www.fibrocellscience.com.